Inflammation and infection in stable coronary disease and the acute coronary syndrome;Inflamación e infección en la enfermedad coronaria estable y en el síndrome coronario agudo

Revista Espanola de Cardiologia

Volumn 54, Issue 4, 2001, Pages 453-459

  Bermejo García, José ^a   Martínez Mart́nez, Prudencio ^a   Martín Rodríguez, José F ^b   De La Torre Carpente, Mar ^a   Bustamante Bustamante, Rosa ^a   Guerrero Peral, Ana B ^a   De Lejarazu, Raúl Ortiz ^a   Eiros Bouza, José M ^a   Blanco García, Santiago ^a   Fernández Avilés, Francisco ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b Departamento de Estadistica   (Spain)

Author keywords

Atherosclerosis; Coronary artery disease; Risk factors

Indexed keywords

IMMUNOGLOBULIN M;

ARTICLE; BACTERIAL INFECTION; BLOOD; CHLAMYDOPHILA PNEUMONIAE; CORONARY ARTERY DISEASE; CYTOMEGALIC INCLUSION BODY DISEASE; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNOLOGY; INFLAMMATION; MALE; MIDDLE AGED; SYNDROME;

CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CORONARY DISEASE; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOGLOBULIN M; INFLAMMATION; MALE; MIDDLE AGED; SYNDROME;

EID: 0041849880     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-8932(01)76333-6     Document Type: Article

References (51)

1. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90: 1-11.
2. Schwartzman RA, Cox ID, Poloniecki JP, CrooK R, Seymour CA, Kaski JC. Elevated plasma lipoprotein (a) is associated with coronary artery disease in patients with chronic stable angina pectoris. J Am Coll Cardiol 1998; 31: 1260-1266.
3. Steinberg D, Parthasarthy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modification of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924.
4. Gilligan DM, Quyyumi AA, Cannon RO. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994; 89: 2545-2551.
5. Kaski JC. Inflamación, infección y enfermedad coronaria. Mitos y realidades. Rev Esp Cardiol 2000; 53: 1311-1317.
6. Fuster V. Mechanism leading to myocardial infarction. Insights from studies of vascular biology. Circulation 1994; 90: 2126-2146.
7. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-2850.
8. Ross R. Atherosclerosis. An inflammatory disease. N Engl J Med 1999; 340: 115-126.
9. García-Moll X, Kaski JC. Cardiopatía isquémica: marcadores de inflamación y riesgo cardiovascular. Rev Esp Cardiol 1999; 52: 990-1003.
10. Patel P, Mendall MA, Carrington D, Strachan E, Molineaux N, Levy J et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. Br Med J 1995; 311: 711-714.
11. Saikku P, Leinonen M, Manila K, Ekman MR, Nieminen MS, Mäkelä PH et al. Serological evidence of an association of a novel Chlamydia, Twar, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983-986.
12. Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS, Daling JR. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 1992; 268: 68-72.
13. Birnie DH, Holme ER, McKays IC, Hood S, McColl KEL, Hillis WS. Association between antibodies to heat shock protein 65 and coronary atherosclerosis. Possible mechanism of action of Helicobacter pylory and other bacterial infection in increasing cardiovascular risk. Eur Heart J 1998; 19: 387-394.
14. Pasceri V, Cammarota G, Patti G, Cuoco L, Gasbarrini A, Grillo RL et al. Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation 1998; 97: 1675-1679.
15. Hosenpud JD. Coronary artery disease after heart transplantation and relation to Cytomegalovirus. Am Heart J 1999; 138: 469-472.
16. Thomas M, Wong Y, Thomas D, Ajaz M, Tsang V, Gallagher PJ et al. Relation between direct detection of Chlamydia pneumoniae DNA in human coronary arteries at postmorten examination and histological severity (Stary grading) of associated atherosclerotic plaque. Circulation 1999; 99: 2733-2736.
17. Maass M, Bartels C, Engel PM, Mamat U, Sievers HH. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. Am J Cardiol 1998; 15: 827-832.
18. Gabay C, Kushner I. Mechanisms of disease: acute-phase proteins and other systemic responses in inflammation. N Engl J Med 1999; 340: 448-454.
19. Kugiyama K, Ota Y, Takazoe K, Moritama Y, Kawano H, Miyao Y et al. Circulating level of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation 1999; 100: 1280-1284.
20. Haught WH, Mansour M, Rothein R, Kihimoto TK, Mainolfi EA, Hendricks JB et al. Alterations in circulating intercellular adhesion molecule-1 and L-selectin: further evidence for chronic inflammation in ischemic heart disease. Am Heart J 1996; 132: 1-8.
21. Hasdai D, Scheinowitz M, Leibivitz E, Sclarowsky S, Eldar M, Barak V. Increased serum concentration of interleukin-1 beta in patients with coronary artery disease. Heart 1996; 76: 24-28.
22. Toss H, Lindahl B, Siegbahn, A, Wallentin L. Prognosis influence of increased tibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during inestabiliy in coronary artery disease. Circulation 1997; 96: 4204-4210.
23. Abdelmouttaleb I, Danchin N, Ilardo C, Aimone-Gastin I, Angioi M, Lozniewski A et al. C-reactive protein and coronary artery disease: additional evidence of the implication of an inflammatory process in acute coronary syndromes. Am Heart J 1999; 137: 346-351.
24. Montaslescot G, Philippe F, Ankri A, Vicaut E, Bearez P, Poulard JE et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin, French investigators of the ESSENCE trial. Circulation 1998; 98: 294-299.
25. Ridker PM, Hennekens CH, Roitman-Jonson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risk of future myocardial infarction in apparently healtly men. Lancet 1998; 10: 88-92.
26. Leibovitz E, Hertz Y, Liberman E, Sclarovsky S, Beliner S. Increased adhesiveness of white blood cell in patients with unstable angina: aditional evidence for an involvement of the immune-inflammatory system. Clin Cardiol 1997; 20: 1017-1020.
27. Tracy RP. Inflammation in cardiovascular disease. Cart, horse or both? Circulation 1998; 97: 2000-2002.
28. Ridker PM, Cushman N, Stampfer MJ, Tracy R, Hennekens CH. Inflammation, aspirin and the risk of cardiovascular disease in apperently healthy men. N Engl J Med 1997; 336: 973-979.
29. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
30. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analysis. Br Med J 2000; 321: 199-204.
31. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A et al. Elevated level of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99: 855-860.
32. Lindahl B, Toss H, Siegbahn A, Venge P, Walentin L, for the FRISC Study Group. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 2000; 343: 1139-1147.
33. Buffon A, Liuzzo G, Biasucci LM, Pascualetti P, Ramazzotti V, Rebuzzi AG et al. Preprocedural serum levels of C-protein reactive predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999; 34: 1512-1521.
34. Bhakdi S. Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999; 19: 2348-2354.
35. Dummer S, Lee A, Breinig MK, Kormos R, Ho M, Griffith B. Investigation of Cytomegalovirus infection as a risk factor for coronary atherosclerosis in the explained hearts of patients undergoing heart transplantation. J Med Virol 1994; 44: 305-309.
36. Adam E, Melnick JL, Probtsfield JL, Petrie BL, Burek J, Bailey KR et al. High level of Cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lancet 1987; 2: 291-293.
37. Rasmussen SJ, Eckmann L, Quayle AJ, Shen L, Zhang YX, Anderson DJ et al. Secretion of proinflammatory cytokines by epithelial cells in response to Chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis. J Clin Invest 1997; 99: 77-87.
38. Frier RH, Schwobe EP, Woods ML, Rodgers GM. Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J Invest Med 1997; 45: 168-174.
39. Gurfinkel E, Bozovich G, Beck A, Testa E, Livellara B. Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wavw coronary syndromes. The final report of the ROXIS study. Eur Heart J 1999; 20: 121-127.
40. Gupta S, Lesthan EW, Carrington D, Mendal MA, Kaski JC, Camm AJ. Elevated Chlamydia pneuimmiae antibodies, cardiovascular events and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-407.
41. Valantine HA, Gao SZ, Menon SG, Renlund DG, Hant SA, Oyer P et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomizaed, placebo-controlled study. Circulation 1999; 100: 61-66.
42. McDonagh TA, Woodward M, Morrison CE, McMurray JJV, Tunstall-Pedoe H, Lowe GDO et al. Helicobacter pylori infection and coronary heart disease in the north Glasgows MONICA population. Eur Heart J 1997; 18: 1257-1260.
43. Quinn MJ, Poky JB, Mulvihill NT, Lee J, Crean PA, Walsh MJ et al. Helicobacter pylori serology in patients with angiographically documented coronary artery disease. Am J Cardiol 1999; 83: 1664-1606.
44. Ridker PM, Hennekens CH, Stampfer MJ, Wang F. Prospective study of herpes simplex virus, Cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation 1998; 98: 2796-2799.
45. Adler SP, Hur JK, Wang JB, Vetrovee GW. Prior infection with Cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. J Infect Dis 1998; 177: 209-212.
46. Altman R, Routivier J, Scazziota A, Absi RS, González C. Lack of assotiation between prior infection with Chamydia pneumoniae and acute or chronic artery disease. Clin Cardiol 1999; 22: 85-90.
47. Danesh J, Wong Y, Ward M, Muir J. Chronic infection with Helicobacter pylori, Chlamydia pneumoniae or Cytomegalovirus: population based study of coronary heart disease. Heart 1999; 81: 245-247.
48. Regnstrom J, Jovinge S, Bavenholm P, Ericsson CG, De Faire U, Hamsten A et al. Helicobacter pylori seropositivity is nor associated with inflammatory parameters, lipid concentrations and degree of coronary artery disease. J Intern Med 1998; 243: 109-113.
49. Anderson JL, Muhleslein JB, Carlquist J, Allen A, Trehan S, Nielson C et al. Randomized secondary prevention trial of azithromicin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: the azithromicin in coronary artery disease: elimination of myocardial infection with Chamydia (ACADEMIC) study. Circulation 1999; 99: 1549-1547.
50. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Applehy P et al. Chamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. Br Med J 2000; 321: 208-212.
51. Dahlen GH, Boman J, Birgander LS, Lindblom B. Lp(a) lipoprotein. IgG. IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. Atherosclerosis 1995; 114: 165-174.